Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
TEL AVIV, Israel, March 02, 2017 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Monday, March 27, 2017 at 8:30am Eastern Time to report fourth quarter and full-year ended December 31, 2016 financial results.
| Monday, March 27th @ 8:30am Eastern Time | |||
| Domestic: | 888-727-7622 | ||
| International: | 913-312-0384 | ||
| Conference ID: | 8563883 | ||
| Webcast: | http://edge.media-server.com/m/p/npmjtb62 | ||
| Replays, available through April 10, 2017: | |||
| Toll Free: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Conference ID: | 8563883 | ||
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC (646) 597-6979
